Fantop

# Fantop ## Overview - **Classification**: Selective Serotonin Reuptake Inhibitor (SSRI) - **Mechanism**: Potent and selective inhibition of serotonin (5-HT) reuptake in the neuronal synapse, leading to increased serotonergic activity in the CNS. ## Primary Indications 1. **Major Depressive Disorder (MDD)** - Treatment of depressive episodes. 2. **Generalized Anxiety Disorder (GAD)** - Management of chronic anxiety. 3. **Panic Disorder (PD)** - Treatment of panic attacks with or without agoraphobia. ## Adult Dosing ### Standard Dosing **Major Depressive Disorder (MDD)** - **Dose**: Start **10 mg** - **Frequency**: Once daily, usually in the morning - **Route**: Oral - **Duration**: Typically long-term; re-evaluate after 6-12 months of remission - **Maintenance**: May increase by **10 mg** increments weekly to **20-40 mg** daily. - **Maximum Dose**: **60 mg** daily **Generalized Anxiety Disorder (GAD)** - **Dose**: Start **5 mg** - **Frequency**: Once daily - **Route**: Oral - **Maintenance**: May increase by **5-10 mg** increments weekly to **10-30 mg** daily. - **Maximum Dose**: **40 mg** daily ### Dose Adjustments - **Renal Impairment**: - CrCl 30-60 mL/min: No initial adjustment; monitor for adverse effects. - CrCl < 30 mL/min: Start at **5 mg** daily; max **20 mg** daily. - **Hepatic Impairment**: - Mild-Moderate: Start at **5 mg** daily; max **30 mg** daily. - Severe: Not recommended; if used, extreme caution and reduced dose (e.g., **5 mg** every other day). - **Elderly Patients (>65 years)**: Start at **5 mg** daily; slower titration recommended. Maximum dose often lower (**30-40 mg** daily). ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not routinely recommended. - **Special Notes**: Limited safety and efficacy data. Use only if potential benefit outweighs risk in severe, refractory conditions under specialist supervision. ### Infants (1-12 months) - **Dose**: Not established for routine use. - **Special Notes**: Safety and efficacy not established. Use with extreme caution under specialist guidance for specific, severe conditions. ### Children (1-12 years) **Major Depressive Disorder (MDD)** / **Generalized Anxiety Disorder (GAD)** - **Dose**: Start **0.1 mg/kg** - **Frequency**: Once daily, usually in the morning - **Maximum**: Do not exceed **10 mg** initial dose. - **Maintenance**: May increase by **0.1 mg/kg** weekly increments up to **0.5 mg/kg** daily. - **Maximum Dose**: **30 mg** daily (or **40 mg** for older children/heavier weight, whichever is lower). - **Special Notes**: Close monitoring for suicidal ideation, especially during initial therapy and dose changes. ### Adolescents (13-18 years) **Major Depressive Disorder (MDD)** / **Generalized Anxiety Disorder (GAD)** - **Dose**: Start **10 mg** - **Frequency**: Once daily - **Maximum**: **60 mg** daily (similar to adult dosing). - **Special Notes**: Monitor for emergent suicidality. Dose titration as per adult recommendations but initiate with lower end of adult range. ## Safety Information ### Contraindications - **Absolute**: Concomitant use with MAOIs (risk of serotonin syndrome). - **Absolute**: Known hypersensitivity to Fantop or excipients. - **Absolute**: Concomitant use with pimozide or thioridazine (due to QTc prolongation risk). - **Relative**: Uncontrolled narrow-angle glaucoma. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, insomnia, headache, diarrhea, dizziness, dry mouth. - **Common (1-10%)**: Somnolence, anxiety, sweating, sexual dysfunction (ejaculation disorder, anorgasmia), tremor, blurred vision. - **Serious but Rare**: Serotonin Syndrome, seizures, hyponatremia, QTc prolongation/arrhythmias, suicidal ideation (especially in children/adolescents). ### Key Drug Interactions - **MAOIs (e.g., phenelzine, selegiline)**: **Contraindicated**. Risk of life-threatening serotonin syndrome. Allow 14 days washout after MAOI, 5 weeks after Fantop. - **Other Serotonergic Agents (e.g., triptans, tramadol, fentanyl, linezolid, St. John's Wort)**: Increased risk of serotonin syndrome. Monitor closely; consider lower doses. - **Anticoagulants (e.g., warfarin) / Antiplatelets (e.g., aspirin, NSAIDs)**: Increased risk of bleeding. Monitor INR/bleeding signs. - **QTc-prolonging drugs (e.g., Class IA/III antiarrhythmics, antipsychotics)**: Increased risk of QTc prolongation. Avoid co-administration if possible. - **CYP2C19/CYP3A4 Inhibitors**: May increase Fantop levels. Consider dose reduction. ## Monitoring & Follow-up - **Before Treatment**: Baseline mental status assessment (e.g., PHQ-9, GAD-7), complete blood count (CBC), electrolytes. Consider ECG if cardiac risk factors or concomitant QTc-prolonging drugs. - **During Treatment**: - Initial 4 weeks: Weekly mental status and adverse effect assessment. - Weeks 4-12: Every 2-4 weeks. - Ongoing: Every 1-3 months. - Monitor for emergent suicidal ideation or unusual behavioral changes, especially in pediatric/adolescent patients. - Electrolytes (sodium) if risk factors for hyponatremia. - **Clinical Signs**: Worsening depression/anxiety, agitation, restlessness, panic attacks, insomnia, impulsivity, irritability, aggression, unusual increases in activity or talking. ## Clinical Pearls - 💡 **Onset of Action**: Therapeutic effects may take **2-4 weeks** to become apparent. Counsel patients on delayed onset. - 💡 **Discontinuation Syndrome**: Taper dose slowly over several weeks when discontinuing to avoid withdrawal symptoms (e.g., dizziness, sensory disturbances, anxiety). - 💡 **Timing**: Can be taken with or without food. If insomnia or activation occurs, consider morning dosing. If somnolence occurs, consider evening dosing. - 💡 **Sexual Side Effects**: Common but often underreported. Discuss potential sexual dysfunction with patients and management strategies. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.